## Ester Orlandi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/715667/publications.pdf

Version: 2024-02-01

109 papers 2,212 citations

218592 26 h-index 276775 41 g-index

109 all docs

109 docs citations

109 times ranked 3447 citing authors

#	Article	IF	CITATIONS
1	Set-up errors analyses in IMRT treatments for nasopharyngeal carcinoma to evaluate time trends, PTV and PRV margins. Acta Oncol $\tilde{A}^3$ gica, 2011, 50, 61-71.	0.8	107
2	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Annals of Oncology, 2012, 23, 1832-1837.	0.6	97
3	Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus. Critical Reviews in Oncology/Hematology, 2015, 96, 372-384.	2.0	95
4	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Annals of Oncology, 2014, 25, 462-466.	0.6	83
5	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	2.0	82
6	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2016, 67, 174-182.	1.3	75
7	Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. Critical Reviews in Oncology/Hematology, 2010, 73, 111-125.	2.0	72
8	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European Journal of Cancer, 2016, 69, 158-165.	1.3	66
9	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	2.0	51
10	Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy for Head and Neck Cancer: Prospective Observational Study Validating CTCAE, Version 3.0, Scoring System. International Journal of Radiation Oncology Biology Physics, 2008, 70, 330-337.	0.4	48
11	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 959-966.	0.4	48
12	What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2122-2138.	3.3	48
13	Salivary Gland. Photon beam and particle radiotherapy: Present and future. Oral Oncology, 2016, 60, 146-156.	0.8	46
14	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. Oral Oncology, 2016, 54, 54-57.	0.8	46
15	Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral Oncology, 2019, 99, 104453.	0.8	43
16	Paranasal sinus cancer. Critical Reviews in Oncology/Hematology, 2016, 98, 45-61.	2.0	41
17	Oropharyngeal Squamous Cell Carcinoma Treated With Radiotherapy or Radiochemotherapy: Prognostic Role of TP53 and HPV Status. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1053-1059.	0.4	39
18	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncology, 2013, 49, 413-419.	0.8	39

#	Article	IF	Citations
19	Big Data in Head and Neck Cancer. Current Treatment Options in Oncology, 2018, 19, 62.	1.3	38
20	Further Improvement in Outcomes of Nasopharyngeal Carcinoma With Optimized Radiotherapy and Induction Plus Concomitant Chemotherapy: An Update of the Milan Experience. International Journal of Radiation Oncology Biology Physics, 2009, 74, 774-780.	0.4	35
21	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Annals of Oncology, 2014, 25, 694-699.	0.6	33
22	Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. Oral Oncology, 2019, 93, 1-7.	0.8	32
23	Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. Oncotarget, 2017, 8, 47780-47789.	0.8	32
24	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Annals of Oncology, 2011, 22, 2495-2500.	0.6	31
25	Prevalence of Fatigue in Head and Neck Cancer Survivors. Annals of Otology, Rhinology and Laryngology, 2019, 128, 413-419.	0.6	30
26	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head and Neck, 2019, 41, 3670-3676.	0.9	29
27	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. Cancers, 2020, 12, 2958.	1.7	29
28	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. Future Oncology, 2013, 9, 103-114.	1.1	28
29	Treatment challenges in and outside a network setting: Head and neck cancers. European Journal of Surgical Oncology, 2019, 45, 40-45.	0.5	27
30	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. European Journal of Cancer, 2020, 136, 35-42.	1.3	27
31	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Annals of Oncology, 2007, 18, 601-602.	0.6	26
32	Radiotherapy for unresectable sinonasal cancers: Dosimetric comparison of intensity modulated radiation therapy with coplanar and non-coplanar volumetric modulated arc therapy. Radiotherapy and Oncology, 2014, 113, 260-266.	0.3	26
33	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	0.8	26
34	Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Followâ€up. Otolaryngology - Head and Neck Surgery, 2019, 161, 635-642.	1.1	26
35	Temporal course and predictive factors of analgesic opioid requirement for chemoradiationâ€induced oral mucositis in oropharyngeal cancer. Head and Neck, 2016, 38, E1521-7.	0.9	25
36	Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1057.	1.7	25

#	Article	IF	Citations
37	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. Laryngoscope, 2020, 130, 857-865.	1.1	25
38	Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Supportive Care in Cancer, 2014, 22, 1889-96.	1.0	23
39	Prevention and treatment of radiation-induced acute dermatitis in head and neck cancer patients: a systematic review. Future Oncology, 2018, 14, 291-305.	1.1	23
40	The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. Supportive Care in Cancer, 2021, 29, 5701-5709.	1.0	23
41	Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2,N0-1): A review. Critical Reviews in Oncology/Hematology, 2019, 143, 67-75.	2.0	21
42	A snapshot on radiotherapy for head and neck cancer patients during the COVID-19 pandemic: a survey of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) head and neck working group. Radiologia Medica, 2021, 126, 343-347.	4.7	21
43	Longâ€term outcome of reâ€rradiation for recurrent or second primary head and neck cancer: A multiâ€nstitutional study of AIROâ€"Head and Neck working group. Head and Neck, 2019, 41, 3684-3692.	0.9	17
44	Sinonasal cancers treatments: state of the art. Current Opinion in Oncology, 2021, 33, 196-205.	1.1	17
45	Contouring of the Pharyngeal Superior Constrictor Muscle (PSCM). A cooperative study of the Italian Association of Radiation Oncology (AIRO) Head and Neck Group. Radiotherapy and Oncology, 2014, 112, 337-342.	0.3	16
46	Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. Radiologia Medica, 2019, 124, 414-421.	4.7	16
47	Postoperative Radiotherapy for Synovial Sarcoma of the Head and Neck during Pregnancy: Clinical and Technical Management and Fetal Dose Estimates. Tumori, 2007, 93, 45-52.	0.6	15
48	What is the role of postoperative re-irradiation in recurrent and second primary squamous cell cancer of head and neck? A literature review according to PICO criteria. Critical Reviews in Oncology/Hematology, 2017, 111, 20-30.	2.0	15
49	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. Value in Health, 2017, 20, 799-808.	0.1	15
50	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. Acta Oncol³gica, 2021, 60, 1192-1200.	0.8	13
51	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. European Journal of Cancer, 2021, 159, 194-204.	1.3	13
52	Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. Supportive Care in Cancer, 2017, 25, 1787-1795.	1.0	12
53	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. Oral Oncology, 2019, 90, 94-101.	0.8	12
54	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2479-2487.	1.2	12

#	Article	IF	CITATIONS
55	Undifferentiated nasopharyngeal carcinoma in children and adolescents: Comparison between staging systems. Annals of Oncology, 2001, 12, 1157-1162.	0.6	11
56	Target Coverage in Head and Neck Cancer Treated with Intensity-Modulated Radiotherapy: A Comparison between Conventional and Conformal Techniques. Tumori, 2006, 92, 503-510.	0.6	11
57	Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Medical Oncology, 2020, 37, 85.	1.2	11
58	Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review. Frontiers in Oncology, 2021, 11, 789079.	1.3	11
59	Personalized Medicine and the Contradictions and Limits of First-Generation Deescalation Trials in Patients With Human Papillomavirus–Positive Oropharyngeal Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 99.	1.2	10
60	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1217-1221.	0.4	9
61	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. Dysphagia, 2019, 34, 52-62.	1.0	9
62	Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. Frontiers in Oncology, 2020, 10, 518110.	1.3	9
63	A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients. Radiation Oncology, 2020, 15, 193.	1.2	9
64	Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates. Tumori, 2007, 93, 45-52.	0.6	9
65	Radiation-induced papillary thyroid cancer: is it a distinct clinical entity?. Current Opinion in Otolaryngology and Head and Neck Surgery, 2019, 27, 117-122.	0.8	8
66	Managing locally advanced adenoid cystic carcinoma of the head and neck during the COVID-19 pandemic crisis: Is this the right time for particle therapy? Oral Oncology, 2020, 106, 104803.	0.8	8
67	Proton Radiation Therapy for Nasopharyngeal Cancer Patients: Dosimetric and NTCP Evaluation Supporting Clinical Decision. Cancers, 2022, 14, 1109.	1.7	8
68	Italian version of the M.D. Anderson Symptom Inventory—Head and Neck Module: linguistic validation. Supportive Care in Cancer, 2015, 23, 3465-3472.	1.0	7
69	Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO). European Archives of Oto-Rhino-Laryngology, 2018, 275, 561-567.	0.8	7
70	Inter-observer variability of clinical target volume delineation in definitive radiotherapy of neck lymph node metastases from unknown primary. A cooperative study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Head and Neck Group. Radiologia Medica, 2019, 124, 682-692.	4.7	7
71	Metastatic salivary gland carcinoma: A role for stereotactic body radiation therapy? A study of AIROâ€Head and Neck working group. Oral Diseases, 2022, 28, 345-351.	1.5	7
72	Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy. Tumori, 2020, 106, 39-46.	0.6	6

#	Article	IF	CITATIONS
73	Investigating DWI changes in white matter of meningioma patients treated with proton therapy. Physica Medica, 2021, 84, 72-79.	0.4	6
74	M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy±Âsystemic therapy – A study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Oral Oncology, 2021, 115, 105189.	0.8	6
75	Quality of life and financial toxicity after (chemo)radiation therapy in head and neck cancer: are there any sex- or gender-related differences?. Tumori, 2022, 108, 522-525.	0.6	6
76	Toward Personalized Cancer Care for Elderly Head and Neck Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 965-966.	0.4	5
77	The Case Volume Issue in Head and Neck Oncology. Current Treatment Options in Oncology, 2017, 18, 65.	1.3	5
78	Target coverage in head and neck cancer treated with intensity-modulated radiotherapy: a comparison between conventional and conformal techniques. Tumori, 2006, 92, 503-10.	0.6	5
79	A Patient Selection Approach Based on NTCP Models and DVH Parameters for Definitive Proton Therapy in Locally Advanced Sinonasal Cancer Patients. Cancers, 2022, 14, 2678.	1.7	5
80	Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers. Tumori, 2018, 104, 213-220.	0.6	4
81	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. Tumori, 2021, 107, 030089162095284.	0.6	4
82	RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?. Oncotarget, 2017, 8, 96184-96189.	0.8	4
83	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. Future Oncology, 2014, 10, 2111-2120.	1.1	3
84	Moderately accelerated intensityâ€modulated radiation therapy using simultaneous integrated boost: Practical reasons or evidenceâ€based choice? A critical appraisal of literature. Head and Neck, 2020, 42, 3405-3414.	0.9	3
85	Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. European Archives of Oto-Rhino-Laryngology, 2021, 278, 771-779.	0.8	3
86	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of AqualiefTM Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. Cancers, 2021, 13, 3456.	1.7	3
87	In Silico Feasibility Study of Carbon Ion Radiotherapy With Simultaneous Integrated Boost for Head and Neck Adenoid Cystic Carcinoma. Frontiers in Oncology, 2021, 11, 772580.	1.3	3
88	Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review. Head and Neck, 2022, 44, 1961-1975.	0.9	3
89	Could the extreme conformality achieved with proton therapy in paranasal sinuses cancers accidentally results in a high rate of leptomeningeal progression?. Head and Neck, 2019, 41, 3733-3735.	0.9	2
90	The day after De-ESCALaTE and RTOG 1016 trials results. Future Oncology, 2019, 15, 2069-2072.	1.1	2

#	Article	IF	CITATIONS
91	The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. Tumori, 2019, 105, NP28-NP31.	0.6	2
92	Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. Cancers, 2020, 12, 3769.	1.7	2
93	Almost one year of COVID-19 pandemic: how radiotherapy centers have counteracted its impact on cancer treatment in Lombardy, Italy. CODRAL/AIRO-L study. Tumori, 2022, 108, 177-181.	0.6	2
94	Treatment Options for Recurrent Anterior Skull Base Tumors. Advances in Oto-Rhino-Laryngology, 2020, 84, 231-245.	1.6	2
95	Dosimetric and Clinical Risk Factors for the Development of Maxillary Osteoradionecrosis in Adenoid Cystic Carcinoma (ACC) Patients Treated With Carbon Ion Radiotherapy. Frontiers in Oncology, 2022, 12, 829502.	1.3	2
96	A year of pandemic for European particle radiotherapy: A survey on behalf of EPTN working group. Clinical and Translational Radiation Oncology, 2022, 34, 1-6.	0.9	2
97	Geometry of volumes in radiotherapy planning. A new method for a quantitative assessment. Tumori, 2011, 97, 503-9.	0.6	2
98	Lower-Neck Sparing Using Proton Therapy in Patients with Uninvolved Neck Nasopharyngeal Carcinoma: Is It Safe?. Journal of Clinical Medicine, 2022, 11, 3297.	1.0	2
99	Comments on "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure―by Chan and Coll. Oral Oncology, 2013, 49, e38.	0.8	1
100	Comment on â€~Human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer'. British Journal of Cancer, 2018, 118, e5-e5.	2.9	1
101	In Reply to Fakhry etÂal. International Journal of Radiation Oncology Biology Physics, 2018, 102, 670-671.	0.4	1
102	Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. Cancers, 2021, 13, 3983.	1.7	1
103	Salivary Gland Tumors: Radiotherapy. , 2019, , 159-193.		1
104	Therapeutic challenges in radiation-induced salivary gland cancers. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 120-125.	0.8	1
105	Role of diffusion-weighted MRI in recurrent rectal cancer treated with carbon ion radiotherapy. Future Oncology, 0, , .	1.1	1
106	A SEGMENTATION PROBLEM IN QUANTITATIVE ASSESSMENT OF ORGAN DISPOSITION IN RADIOTHERAPY. Image Analysis and Stereology, 2011, 30, 179.	0.4	0
107	Comment on â€~Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base'. British Journal of Cancer, 2015, 113, 1638-1639.	2.9	0
108	Management of Salivary Gland Cancer. , 2016, , 625-640.		O

# ARTICLE IF CITATIONS

109 Radiotherapy and Medical Treatment., 2020,, 47-56. 0